Introduction

E
XCESS IODIDE inhibits the thyroid by multiple mechanisms (1) . It causes acute inhibition of thyroid hormone synthesis and release (acute Wolff-Chaikoff effect). Furthermore, it inhibits blood flow, particularly in the hypervascular thyroid gland of patients with Graves' disease (2, 3) . This phenomenon is well known to surgeons, and for many years potassium iodide has been routinely administered to patients with Graves' disease before undergoing subtotal thyroidectomy (4) . However, the mechanism by which excess iodine decreases blood flow remains to be elucidated (5) . The iodine-induced decrease of thyroidal blood flow is not restricted to hyperthyroid subjects: in euthyroid humans, low (1.3 mol/d) to high iodine (80 mol/d) intake has been reported to decrease thyroid blood flow by 44%, without significant change in serum thyrotropin (TSH) levels, suggesting that iodide directly regulates thyroid blood flow (6) . In addition to increased blood flow, the thyroid gland has well developed lymphatic capillaries (7) and lymph flow is also increased in the hyperthyroid gland of patients with Graves' disease (8) .
The vascular endothelial growth factor (VEGF) family is involved in angiogenesis and lymphangiogenesis in various endocrine glands (5, 9) . Previously, we reported that TSH and Graves' immunoglobulin (IgG) increase the expression level of VEGF mRNA in human thyroid follicles in vitro and increase VEGF secretion, which stimulates endothelial cell proliferation in a paracrine fashion, leading to hypervascularity of the thyroid gland (10) .
To elucidate the regulatory mechanism of blood flow in the hyperfunctional thyroid gland, we studied the effects of TSH and iodide in cultured human thyroid follicles, which maintain thyroid hormonogenesis in response to physiologic concentrations of TSH (11) and exhibit Wolff-Chaikoff effects in the presence of high concentrations of iodide (12) . Because there are a number of factors that stimulate or inhibit angiogenesis in the thyroid gland (13, 14) , we analyzed gene ex-pression levels using oligo-DNA microarray, by which 41,000 gene spots (i.e., the entire human genome [15] ), can be analyzed in a single run.
Materials and Methods
Suspension culture of human thyroid follicles
Informed consent was obtained from all patients with Graves' disease before they underwent subtotal thyroidectomy. All the patients were routinely treated with iodide (10-30 mg/d) and antithyroid agents (usually methimazole) for 7-14 days prior to subtotal thyroidectomy. Human thyroid follicles were cultured as reported previously (10) (11) (12) 16) . In brief, thyroid tissue (15-30 g ) was obtained from patients with Graves' disease during subtotal thyroidectomy and minced into small pieces with scissors. The prepared tissues were then digested with 0.3 mg/mL collagenase (type IV; Worthington Chemical Co., Funakoshi, Tokyo, Japan) and 5 mg/mL dispase (Godo Shusei Co., Tokyo, Japan) in Hanks' balanced salt solution at 32°C for 30 minutes. The digested material was filtered through a nylon mesh (80 mesh), and any undigested tissue fragments were processed for a second time. The resulting filtrate, containing separated thyroid follicles, was centrifuged at 800 rpm for 1 minute, then the pellet was washed three times with F-12/RPMI-1640 (1:1) medium supplemented with 0.5% fetal bovine serum, and NaI (10 Ϫ8 M) [low sodium iodide [NaI] medium], until it became white. By this mild centrifugation procedure, thyroid follicles were separated from erythrocytes and mononuclear cells, although a few immunocompetent cells that had infiltrated into the thyroid follicles could not be removed (12) . Then, the thyroid follicles, suspended in 15 mL of the low NaI medium (approximately 1000-2000 follicles per milliliter), were added to 10-cm dishes, the bottoms of which had been coated with agarose.
Effect of TSH on gene expression
After 5 days of preculture in 0.5% fetal calf serum (FCS) plus low Nal medium, the medium was changed and the thyroid follicles were cultured in 0.5% FCS plus low Nal medium with or without bovine thyrotropin (bTSH) (30 U/mL) for an additional 2-3 days, and then total RNA was prepared for microarray analyses as described below.
Effect of iodide on gene expression in thyroid follicles
After 5 days of preculture in 0.5% FCS plus low Nal medium, the medium was changed and the thyroid follicles were cultured in fresh 0.5% FCS plus low (10 Ϫ8 M) Nal medium containing 30 U/mL bTSH. On the following day, NaI solution (10 Ϫ3 M) was added to adjust the final concentration to 2 ϫ 10 Ϫ5 M. To the control culture, only distilled water (150 L) was added. After the culture medium had been gently mixed, the thyroid follicles were cultured for an additional 48 hours in the presence of bTSH (30 U/mL), and then total RNA was prepared for microarray analyses as described below.
In several experiments, thyroid follicles were cultured in 0.5% FCS plus low NaI for several days, and then cultured in the medium containing bTSH (30 U/mL) and various concentrations of iodide (10 Ϫ8 -10 Ϫ5 M). After an appropriate culture period, total RNAs were prepared, and TSH or iodide-induced genes were analyzed by real-time polymerase chain reaction (PCR).
RNA extraction
Total RNA was extracted from thyroid follicles using the RNeasy Minikit (Quiagen, Tokyo, Japan) according to the manufacturer's suggested protocol. Concentration and purity was determined using a Gene Quant spectrophotometer. The quality of RNA was checked by electrophoresis of 1-g samples in a 1.0% formaldehyde agarose gel, followed by staining with ethidium bromide. The 28S and 18S rRNA bands were examined on a UV transilluminator. No significant degradation was observed in any of the RNA samples.
Oligo-DNA microarray
After RNA had been extracted, it was converted to cDNA using a Human cDNA System I Direct kit (NEN Life Science Products, Boston, MA). cDNA obtained from thyroid follicles cultured in the control and treated media were labeled with Cy3 (green, control) and Cy5 (red, TSH or iodide), respectively, and expression levels of 41,000 gene spots were analyzed using cDNA microarray (Whole Human Genome Oligo Microarray Kit, Product Number G4112A; Agilent Technologies, Palo Alto, CA).
Laser detection of the Cy3 and Cy5 signals on the microarray was performed with a nonconfocal laser leader, Gene PX 4000A (Axon Instruments, Union, CA). Fluorescence signal intensities and the Cy5/Cy3 ratios for each of the 41,000 oligo-DNAs were analyzed using the Gene PixPro 30 software package (Axon Instruments).
Real-time RT-PCR
Total RNA (250 ng) was reverse-transcribed in a total reaction volume of 100 L using the high-capacity cDNA archive kits (Applied Biosystems, Foster City, CA) as described by the manufacturer. Complementary DNA was synthesized using a thermal cycler (program temperature control system PC-7000, ASTEK, Fukuoka, Japan) by incubating at 25°C for 10 minutes, and 37°C for 120 minutes. Singlestranded cDNA products were then analyzed by real-time PCR using the TaqMan Gene Expression Assays according to the manufacturer's instructions (Applied Biosystems). Single-stranded cDNA products were analyzed using the ABI PRISM 7700 Sequence Detector (Applied Biosystems). Five assays were performed, VEGF-A (Hs00173626-m1), VEGF-B (Hs00173634-m1), VEGF-C (Hs00153458-m1), tissue-type plasminogen activator (Hs00263492-m1), and urokinase-type plasminogen activator (Hs00170182-m1), using 18S rRNA (Hs99999901-s1) as control. The PCR thermal cycle conditions were set at 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
In each case, triplicate threshold cycle (Ct) values were obtained and averaged; then expression levels were evaluated by a relative quantification method. The fold change in target genes (VEGFs, urokinase-type plasminogen activator [PLAU] ) was normalized to the 18S rRNA (reference gene) and compared to the control sample (calibrator sample), using the following formula: Fold change ϭ 2 Ϫ⌬⌬Ct , where ⌬⌬Ct ϭ (Ct-target-Ct-reference)sample-n Ϫ (Ct-target Ϫ Ct-reference)calibrator-sample. Sample-n corresponds to any sample for the target gene normalized to the reference gene and calibrator-sample represents the expression level (1ϫ) of the target gene normalized to the reference gene.
Northern blot hybridization
Northern blot hybridization was performed as described previously (10) .
VEGF-A concentrations in the conditioned medium
Conditioned medium was stored at Ϫ80°C until assayed for cytokines. VEGF-A concentrations were determined using a sandwich enzyme immunoassay kit (Quantikine, R&D Systems, Minneapolis, MN). The assay kit was designed to measure VEGF 165 in the culture medium, with a detection limit of less than 5 pg/mL.
Statistical analysis
All data are expressed as mean Ϯ standard deviation (SD). Differences among multiple groups were analyzed using analysis of variance (ANOVA). Differences between two groups were compared using unpaired t test, and were considered significant at p Ͻ 0.05.
Results
Effects of TSH on gene expression in human thyroid follicles
As shown in Figure 1 , oligo-DNA microarray analysis revealed that TSH upregulated approximately 1400 genes more than 2-fold and downregulated nearly 1000 genes to less than one half after 48 hours of incubation. Qualitatively similar findings were observed after 24 hours of culture in two other experiments (data not shown). As expected, the most abundantly expressed genes were thyroglobulin and peroxidase, and TSH increased their expression levels more than 7-and 15-fold, respectively (Table 1A) . TSH also increased the expression levels of sodium iodide symporter (NIS), and type I and II deiodinases (17, 18) . Consistent with previous reports (19, 20) , type II deiodinase was expressed more abundantly than type I deiodinase, and TSH stimulated the former to a greater extent than the latter.
As we have reported previously (10), TSH stimulated the VEGF-A expression level approximately threefold, and also increased the expression levels of VEGF-B nearly twofold, and placental growth factor (PGF) by 60% (21) ( Table 1B [a]). Contrary to our expectation (14) , TSH decreased the expression level of VEGF-C by less than one half, with no significant change in VEGF-D expression. The expression level of endocrine gland-derived VEGF (EG-VEGF, prokineticin 1; PROK1), which regulates angiogenesis in steroid-producing endocrine glands (22) , was not modulated by TSH.
Among various angiogenesis factors, FGF-1 and FGF-2, which are elevated in hyperplastic thyroid tissue (23) , were moderately expressed in control thyroid follicles, but their expression levels were not increased by TSH (24) . This was also the case with other FGFs with proangiogenic activity (FGF-5, FGF-7) (5). The level of angiopoietin-1 (ANGPT1) was only slightly increased by TSH. Tie-2, the receptor for angiopoietin-1 and -2, which is known to be expressed in thyrocytes and endothelial cells (25) , was expressed in thyroid follicles but its expression level was not significantly modulated by TSH.
Among various antiangiogenic factors, angiopoitin-2, an antagonist for anigiopoitin-1, which is usually expressed in endothelial cells, was hardly expressed in the present thyroid follicles from which endothelial cells had been almost totally depleted during their preparation (16) . Consistent with a recent report (26) , thyroid follicles expressed plasminogen activators capable of producing angiostatin from plasminogen. TSH decreased both tissue-type (PLAT) and PLAU plasminogen activators by 50% and 30%, respectively (Table 1B[b] ). Thyroid follicles also expressed thyrombospondin-1, -2, and -3, which were not modulated by TSH (26) .
As reported previously (27) , TSH stimulated the expres-
FIG. 1.
Scatter plot of effect of thyrotropin (TSH) on gene expression in human thyroid follicles. Thyroid follicles were precultured in low-iodide (10 Ϫ8 M) medium without TSH for 5 days, and then cultured in the presence (30 U/mL) or absence of bovine thyrotropin (bTSH) for 48 hours. mRNA was isolated to prepare cDNA. Cy3 (TSH(Ϫ))-or Cy5(TSH(ϩ))-labeled cDNA was hybridized to the spots on the microarray. A scatter plot of the hybridization signals is shown after processing the raw data, as described in Materials and Methods. The genes unaffected by TSH correspond to the spots on the grey line. Those on the red lines represent the genes the mRNAs of which were either increased or decreased twofold in the presence of TSH. The arrows in the left upper area indicate the genes for thyroglobulin (Tg), thyroid peroxidase (TPO), type II deiodinase (DIO2), vascular endothelial growth factor (VEGF)-A, and sodium iodide symporter (NIS), mRNA levels of which were increased more than twofold by TSH. In contrast, the arrows in the right lower area indicate VEGF-C and urokinase-type plasminogen activator (PLAU), the mRNA levels of which were decreased to less than one half by TSH. PLAT, tissue-type plasminogen activator, DIO3, type III deiodinase. sion levels of enzymes participating in carbohydrate and lipid metabolism, such as adenosine triphosphate (ATP) synthase, aldolase, creatine kinase, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Table 1C) . Furthermore, prion mRNA was also stimulated by TSH (Table 1D ) (28) .
Effects of iodide on gene expression in human thyroid follicles
As shown in Figure 2 , oligo-DNA microarray analysis revealed that iodide at higher concentration (2 ϫ 10 Ϫ5 M), in comparison with culture at low concentration (10 Ϫ8 M), upregulated the expression of more than 40 genes more than twofold and downregulated that of more than 60 genes (such as sodium iodide symporter [NIS]) to less than one half after 48 hours. A qualitatively similar phenomenon was observed after 24 hours incubation with 10 Ϫ5 M iodide in two other experiments (data not shown).
Iodide at high concentration decreased the expression level of VEGF-A to nearly one half after 48 hours of culture (Table 2B [a]). It also downregulated the expression levels of VEGF-B and PGF by 40% and 50%, respectively. In contrast, the expression level of VEGF-C was increased by 50%. Iodide did not modulate the expression levels of FGF-1, FGF-2, or angiopoietin-1. Consistent with previous reports (29, 30 ), iodide increased the expression level of transforming growth factor (TGF)-␤ 1 by nearly 70%. Furthermore, iodide also increased the expression level of urokinase-type plasminogen activator more than twofold, whereas the expression levels of tissue-type plasminogen activator, thrombospondins and metalloproteinases were not significantly modulated by iodide (Table 2B [b]). As expected, adenylate kinase 1, which was activated more than fourfold by TSH, was suppressed to 50% by iodide (Table 1D and 2D) (1).
Real-time PCR analyses of effects of TSH and iodide on gene expression levels of the VEGF family and plasminogen activators
To confirm the effects of TSH and iodide on VEGF family genes obtained by DNA-microarrays, real-time PCR analyses were performed. When thyroid follicles that had been cultured in medium containing TSH and 10 Ϫ8 M iodide were cultured in medium containing various concentrations of iodide (10 Ϫ8 -10 Ϫ5 M), iodide dose-dependently decreased the expression levels of the TSH-induced VEGF-A and VEGF-B mRNA at 24 and 72 hours of culture ( Fig. 3A and 3B ). Consistent with these findings, iodide dose-dependently decreased the concentration of VEGF-A in the conditioned medium (Fig. 3A) . Time course studies revealed that iodide at 10 Ϫ5 M inhibited the expression of VEGF-A and VEGF-B at 12 hours, and that this inhibitory effect continued for 72 hours (Fig.4 ) . In contrast to VEGF-A and VEGF-B, the decrease in the expression level of VEGF-C induced by TSH was increased by iodide in a concentration-dependent manner (Fig. 3C) . Time course studies revealed that iodide (10 Ϫ5 M) increased VEGF-C expression after 12 hours of culture, and that this stimulatory effect continued for 72 hours (Fig. 4) .
As shown in Figure 5A , iodide increased the expression level of urokinase-type plasminogen activator in a concentration-dependent manner, the stimulatory effect peaking to fivefold at 12 hours of culture and gradually decreasing thereafter, whereas it did not significantly modulate the expression of tissue-type plasminogen activator (Fig. 5B) .
Effects of iodide on VEGF-A mRNA expression revealed by Northern blotting
Northern blot analyses also revealed that TSH increased the steady-state mRNA expression level of VEGF-A, and that this TSH-induced VEGF mRNA expression was decreased by iodide at 10 Ϫ6 M (Fig. 6 ).
Discussion
Using human thyroid follicles in suspension culture, in which de novo synthesized thyroid hormones are released in response to physiologic concentrations of TSH and WolffChaikoff effects are well maintained, we have demonstrated that VEGF-A and VEGF-C are differentially regulated by TSH and iodide. Most importantly, we have demonstrated
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FIG. 2.
Scatter plot of effect of iodide on gene expression in human thyroid follicles. Thyroid follicles were cultured as described in Materials and Methods. The medium was changed to low-(10 Ϫ8 M) or high-iodide medium (2 ϫ 10 Ϫ5 M). After additional culture for 48 hours, mRNA was isolated to prepare the cDNA. Cy3 (10 Ϫ8 M)-or Cy5 (2 ϫ 10 Ϫ5 M)-labeled cDNA was hybridized to the spots on the microarray. A scatter plot of the hybridization signals is shown after processing the raw data, as described in Materials and Methods. The genes unaffected by iodide correspond to the spots on the grey line. Those on the red lines represent the genes whose mRNAs were either increased or decreased twofold in the presence of iodide. Note that iodide increased urokinase-type plasminogen activator (PLAU) expression more than 2-fold, whereas it decreased VEGF-A expression to nearly one half. VEGF, vascular endothelial growth facor; PLAT, tissue-type plasminogen activator; DIO2, type II deiodinase; DIO3, type III deiodinase; NIS, sodium iodide symporter. for the first time that iodide at high concentrations decreases the expression of VEGF-A, accompanied by a decrease of VEGF-A release into the conditioned medium. Although there are a number of angiogenesis factors, VEGF-A, which is produced in 100-fold excess compared to FGF-2 in thyroid follicular cells (31) , is the most potent angiogenesis factor and plays a key role in both physiologic and pathologic angiogenesis (5). Although there are currently more than 20 FGFs, those possessing proangiogenic activity such as FGF-1, FGF-2, and to a lesser extent FGF-3, FGF-5, and FGF-7 (5), were not significantly modulated by TSH. A number of factors are reported to stimulate VEGF-A expression, such as TSH receptor stimulators, growth factors, insulin, insulin-like growth factor (IGF)-1, various cytokines and hypoxia (5,9,10), however, the mechanism responsible for negative regulation is not well elucidated. It is well
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FIG. 3.
Effects of iodide concentration on gene expression levels of vascular endothelial growth factor (VEGF)-A, VEGF-B, and VEGF-C and VEGF-A concentration in the conditioned medium. Thyroid follicles were cultured as described in Materials and Methods. Then, the medium was changed to medium containing various concentrations of iodide (10 Ϫ8 -10 Ϫ5 M). After additional culture for 24 or 72 hours, total RNA was prepared and real time-polymerase chain reaction (PCR) was performed as described in Materi known that excess iodide inhibits the thyroid by multiple mechanisms (1) . Because the expression of VEGF-A mRNA is regulated by the protein kinase A and C pathway (10, 32) , and iodide at high concentrations inhibits TSH-induced cyclic adenosine monophosphate (cAMP) production (1), it is highly likely that iodide inhibited the expression of VEGF-A mRNA through inhibition of TSH receptor-signal transduction, at least via the protein kinase A pathway. In accordance with the dose-dependent decrease in the expression of VEGF-A mRNA induced by iodide, iodide also decreased the VEGF-A concentration in the conditioned medium. It should be pointed out that the present assay measured only the secretable form of VEGF isoforms, chiefly VEGF 165 . If VEGF 189 and VEGF 206 , which are almost completely sequestered in the extracellular matrix (33), had also been determined, the iodide-induced decrease of VEGF synthesis would have been more remarkable (5). Recently Suzuki et al. (34) found that thyroglobulin added to the culture medium of FRTL-5 cells in monolayer culture, dose-and time-dependently decreased TSH-induced thyroid function, in terms of parameters such as the mRNA expression of NIS, thyroid peroxidase (TPO), thyroglobulin, and VEGF-A, and proposed that thyroglobulin accumulated in the follicular lumen is a negative feedback regulator of TSHincreased follicular functions. Our present in vitro findings suggest that dose-dependent suppression of VEGF-A expression by iodide is mediated not only by the thyroglobulin concentration in the follicular lumen but also by the iodine content of thyroglobulin in thyroid follicles, although it remains to be elucidated whether underiodinated and overiodinated thyroglobulin increases or decreases VEGF-A mRNA expression, respectively.
Iodide, when administered in excess to hyperthyroid patients, decreases acutely the synthesis and release of thyroid hormone (acute Wolff-Chaikoff effect), accompanied by a decrease of blood flow in hyperthyroid and euthyroid subjects. It is interesting that TSH increased the expression levels of VEGF-A, VEGF-B, and PGF (10,21) whereas iodide reciprocally decreased the expression of all three. Because VEGF-A, VEGF-B, and PGF stimulate VEGF receptor (VEGFR) 1 and VEGF-A also stimulates VEGFR-2 (5), these angiogenesis factors, when their expression levels are stimulated or inhibited, would synergistically increase or decrease thyroid blood flow, respectively, via synergistic effects on endothelial proliferation and angiogenesis (35) .
In contrast to VEGF-A, the most potent angiogenesis factor, the expression level of VEGF-C, a potent lymphangiogenesis factor, was not stimulated but decreased by TSH. A nonstimulatory effect of TSH on VEGF-C has also been reported in several papillary thyroid carcinoma cell lines (36) . In contrast to VEGF-A, the regulatory mechanism of VEGF-C gene expression is not well elucidated. In human lung fibroblasts, interleukin (IL)-1␣ and IL-1␤, and tumor necrosis factor (TNF)-␣, increase the steady-state levels of VEGF-C mRNA, but hypoxia has no effect on the mRNA levels of VEGF-B or VEGF-C (37). VEGF-C mRNA expression is also upregulated by serum and various growth factors, such as platelet-derived growth factor, epidermal growth factor, TGF-␤, and the tumor promoter phorbol myristate 12,13-acetate (38) . Because iodide stimulates TGF-␤ mRNA expression (29, 30) , the iodide-induced increase of VEGF-C mRNA expression may be at least partly mediated via TGF-␤. Al-
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FIG. 5.
Effects of various concentrations of iodide and culture period on gene expression levels of plasminogen activators. Thyroid follicles were cultured as described in Materials and Methods. The medium was then changed to medium containing various concentrations of iodide (10 Ϫ8 -10 Ϫ5 M). After an additional culture for 24 hours, the expression level of urokinase-type plasminogen activator was determined by real-time polymerase chain reaction (PCR) (A). Blank column: TSH(Ϫ), hatched column: TSH (ϩ). #p Ͻ 0.001, TSH(Ϫ) vs. TSH(ϩ), *p Ͻ 0.01, **p Ͻ 0.001, NaI (10 Ϫ8 M) vs. NaI (10 Ϫ7 -10 Ϫ5 M). After thyroid follicles had been cultured in high-iodide (2 ϫ 10 Ϫ5 M) medium for 1, 5, 12, 24, 48, or 72 hours, total RNA was prepared and realtime PCR was performed as described in Materials and Methods (B) *p Ͻ 0.05, ***p Ͻ 0.001, Control versus hours after medium change: urokinase-type plasminogen activator ᭹-᭹, tissue-type plasminogen activator ᭺-᭺. All data are mean Ϯ standard deviation (SD) of triplicate cultures. TSH, thyrotropin; NaI, sodium iodide.
FIG. 6.
Effect of high iodide concentration on vascular endothelial growth factor (VEGF)-A mRNA expression in human thyroid follicles. Thyroid follicles were precultured in low-iodide (10 Ϫ8 M) medium in the presence or absence of bovine thyrotropin (bTSH; 10 U/mL) for 5 days, and then cultured in high-iodide (10 Ϫ6 M) medium. After an additional culture for 72 hours, total RNA was prepared. Total RNA (10 g per lane) was used for Northern blot hybridization, using 32 P-labeled human VEGF-A cDNA and ␤-actin cDNA as a probe.
though TGF-␤ inhibits angiogenesis in vitro, it participates as an angiogenesis factor in vivo (39) . Therefore, the role of TGF-␤ in angiogenesis in the thyroid gland remains to be elucidated.
There are several endogenous angiogenesis inhibitors that can antagonize angiogenesis induced by proangiogenetic factors (5) . Angiostatin, the most potent angiogenesis inhibitor (40) , is produced by plasminogen activators (tissue-type and urokinase-type plasminogen activator, or streptokinase) by proteolysis of plasminogen in the presence of sulfhydryl donors (L-cystein, reduced glutathione) (41) . More recently, Ramsden et al. (26) reported that thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. Our present microarray analyses confirmed their findings, and furthermore revealed that iodide increased the expression level of urokinase-type plasminogen activator in a time-and dose-dependent manner. It remains to be demonstrated whether conditioned medium of thyroid follicles cultured in medium containing a high iodide concentration would produce angiostatin when cultured with plasminogen in the presence of N-acetylcysteine (26) . In any event, the present data suggest that the iodide-induced decrease of thyroid blood flow may occur through a multifactorial mechanism involving decreased production of proangiogenetic factors (principally, VEGF-A) and increased production of antiangiogenetic factors (possibly angiostatin). Furthermore, the decreased serum levels of triiodothyronine (T 3 ) and thyroxine (T 4 ) caused by the acute Wolff-Chaikoff effect also play a role in decreasing heart rate and cardiac output, leading to decreased blood flow in the thyroid gland.
VEGF-A, which has also been purified as a vascular permeability factor, may be involved not only in accumulation of cyst fluid in follicular adenoma or multinodular goiter (42) , but also in increased lymph flow in the hyperthyroid Graves' thyroid gland, via fenestration formation in endothelial cells (43) . Although iodide increased the expression level of VEGF-C by nearly 50%, VEGF-C is four to five times less potent in the vascular permeability assay (44) . We therefore speculate that iodide treatment decreases not only thyroid hypervascularity but also vascular permeability under hyperthyroid conditions. These in vitro findings may explain the effect of iodide administration to hyperthyroid patients prior to thyroid surgery to reduce bleeding and oozing during the operation, an approach that has been used empirically and routinely by endocrine surgeons for many years (45) .
In summary, using microarray analysis that can analyze the whole human genome in a single run, we have demonstrated that iodide at high concentration decreases the expression level of the angiogenic factors VEGF-A, VEGF-B, and PGF, accompanied by an increase in the expression of possible anti-angiogenic factors such as urokinase-type plasminogen activator, which is capable of synthesizing angiostatin from plasminogen. These proangiogenic and antiangiogenic factors may at least partly account for the iodide-induced decrease in thyroidal blood flow.
